Hoffmann-La Roche

Scottsdale, Arizona

OncologyantibodyFiled/ApprovedListed · RHHBY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

5d agoTrial registeredJul 14, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE1 registered
Jul 31, 2026
Metastatic Colorectal Cancer · NOT_YET_RECRUITING · sponsor: Hoffmann-La Roche · A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
ClinicalTrials.gov · NCT07416552 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Jul 14, 2026
Hemophilia A · RECRUITING · sponsor: Hoffmann-La Roche · A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
ClinicalTrials.gov · NCT07226206 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jul 2, 2026
Healthy Participants · RECRUITING · sponsor: Hoffmann-La Roche · A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants
ClinicalTrials.gov · NCT07626515 (opens the source filing in a new tab)
Trial
PHASE3 registered
Mar 16, 2026
Obesity or Overweight · RECRUITING · sponsor: Hoffmann-La Roche · A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
ClinicalTrials.gov · NCT07351045 (opens the source filing in a new tab)
Trial
PHASE2 registered
Mar 10, 2026
Progressive Multiple Sclerosis · RECRUITING · sponsor: Hoffmann-La Roche · A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
ClinicalTrials.gov · NCT07282574 (opens the source filing in a new tab)
Trial
PHASE3 registered
Nov 12, 2025
Alzheimers Disease · RECRUITING · sponsor: Hoffmann-La Roche · A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
ClinicalTrials.gov · NCT07170150 (opens the source filing in a new tab)
Trial
PHASE2 registered
Aug 19, 2025
Type 2 Diabetes Mellitus · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
ClinicalTrials.gov · NCT07112872 (opens the source filing in a new tab)
Trial
PHASE1 registered
Feb 13, 2025
Healthy Participants · COMPLETED · sponsor: Hoffmann-La Roche · A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081
ClinicalTrials.gov · NCT06809608 (opens the source filing in a new tab)
Trial
PHASE3 registered
Nov 15, 2023
Thyroid Eye Disease · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
ClinicalTrials.gov · NCT06106828 (opens the source filing in a new tab)
Trial
PHASE3 registered
Sep 18, 2023
Large B-Cell Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
ClinicalTrials.gov · NCT06047080 (opens the source filing in a new tab)
Trial
PHASE3 registered
Jun 28, 2023
Chronic Obstructive Pulmonary Disease · RECRUITING · sponsor: Hoffmann-La Roche · A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
ClinicalTrials.gov · NCT05878769 (opens the source filing in a new tab)
Trial
PHASE3 registered
Mar 23, 2023
Uveitic Macular Edema · COMPLETED · sponsor: Hoffmann-La Roche · Vamikibart in Participants With Uveitic Macular Edema
ClinicalTrials.gov · NCT05642325 (opens the source filing in a new tab)
Trial
PHASE2/PHASE3 registered
Feb 27, 2023
Cancer · TERMINATED · sponsor: Hoffmann-La Roche · Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice
ClinicalTrials.gov · NCT05694013 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Nov 16, 2022
Mature B-Cell Non-Hodgkin Lymphoma · RECRUITING · sponsor: Hoffmann-La Roche · A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
ClinicalTrials.gov · NCT05533775 (opens the source filing in a new tab)
Trial
PHASE3 registered
Sep 27, 2022
NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
ClinicalTrials.gov · NCT05503264 (opens the source filing in a new tab)
Trial
PHASE4 registered
Jun 20, 2022
Severe Hemophilia A, Moderate Hemophilia A · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
ClinicalTrials.gov · NCT05181618 (opens the source filing in a new tab)
Trial
PHASE3 registered
Jun 14, 2022
Non-Small Cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
ClinicalTrials.gov · NCT05047250 (opens the source filing in a new tab)
Trial
PHASE2/PHASE3 registered
Jun 2, 2022
Spinal Muscular Atrophy (SMA) · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy
ClinicalTrials.gov · NCT05115110 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jan 11, 2022
Systemic Lupus Erythematosus · COMPLETED · sponsor: Hoffmann-La Roche · A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus
ClinicalTrials.gov · NCT05155345 (opens the source filing in a new tab)
Trial
PHASE3 registered
Oct 27, 2021
Relapsed or Refractory Follicular Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
ClinicalTrials.gov · NCT04712097 (opens the source filing in a new tab)
Trial
PHASE3 registered
Sep 30, 2021
Carcinoma, Non-Small-Cell Lung · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
ClinicalTrials.gov · NCT04603807 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Sep 14, 2021
ALK Fusion-positive Solid or CNS Tumors · RECRUITING · sponsor: Hoffmann-La Roche · A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
ClinicalTrials.gov · NCT04774718 (opens the source filing in a new tab)
Trial
Study registered
May 10, 2021
NSCLC · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib
ClinicalTrials.gov · NCT04764188 (opens the source filing in a new tab)
Trial
PHASE3 registered
May 4, 2021
Carcinoma, Hepatocellular · TERMINATED · sponsor: Hoffmann-La Roche · A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
ClinicalTrials.gov · NCT04732286 (opens the source filing in a new tab)
Trial
PHASE3 registered
May 4, 2021
Breast Cancer · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
ClinicalTrials.gov · NCT04873362 (opens the source filing in a new tab)
Trial
PHASE2 registered
Mar 31, 2021
Autism Spectrum Disorder (ASD) · COMPLETED · sponsor: Hoffmann-La Roche · A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
ClinicalTrials.gov · NCT04299464 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Mar 15, 2021
Alzheimers Disease · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
ClinicalTrials.gov · NCT04639050 (opens the source filing in a new tab)
Trial
PHASE3 registered
Nov 26, 2020
Multiple Sclerosis · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
ClinicalTrials.gov · NCT04544436 (opens the source filing in a new tab)
Trial
PHASE2 registered
Nov 25, 2020
Diabetic Macular Edema · COMPLETED · sponsor: Hoffmann-La Roche · A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab
ClinicalTrials.gov · NCT04597918 (opens the source filing in a new tab)
Trial
PHASE1 registered
Nov 11, 2020
Multiple Myeloma · COMPLETED · sponsor: Hoffmann-La Roche · A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)
ClinicalTrials.gov · NCT04557150 (opens the source filing in a new tab)
Trial
Study registered
Aug 27, 2020
Solid Tumours · COMPLETED · sponsor: Hoffmann-La Roche · A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test
ClinicalTrials.gov · NCT04529122 (opens the source filing in a new tab)
Trial
PHASE3 registered
Aug 25, 2020
Carcinoma, Hepatocellular · COMPLETED · sponsor: Hoffmann-La Roche · A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
ClinicalTrials.gov · NCT04487067 (opens the source filing in a new tab)
Trial
PHASE3 registered
Sep 30, 2019
Diabetic Macular Edema · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
ClinicalTrials.gov · NCT04108156 (opens the source filing in a new tab)
Trial
Study registered
Nov 12, 2018
Multiple Sclerosis · COMPLETED · sponsor: Hoffmann-La Roche · Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
ClinicalTrials.gov · NCT03593590 (opens the source filing in a new tab)
Trial
PHASE3 registered
Nov 16, 2017
Diffuse Large B-Cell Lymphoma · COMPLETED · sponsor: Hoffmann-La Roche · A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
ClinicalTrials.gov · NCT03274492 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Oct 13, 2017
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma · COMPLETED · sponsor: Hoffmann-La Roche · A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
ClinicalTrials.gov · NCT03281369 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.96name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.70name similarity 100% · shared principal investigator / founder
new_entity links the trial record at 0.25same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
5d agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
5d agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
1w agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
1w agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
1w agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib
1w agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
1w agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors
1w agoTrial recruitingSource (opens the source filing in a new tab)
Phase I trial registered: A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
1w agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
2w agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
2w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
2w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
2w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
2w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
3w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
3w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
3w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
3w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
4w agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab
4w agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab
4w agoTrial completedSource (opens the source filing in a new tab)
Phase III trial registered: An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
4w agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy
5w agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
7w agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test
7w agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test
7w agoTrial completedSource (opens the source filing in a new tab)
Phase III trial registered: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
2mo agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
2mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
2mo agoTrial completedSource (opens the source filing in a new tab)
Phase III trial registered: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
2mo agoTrial registeredSource (opens the source filing in a new tab)
Filed/Approved trial registered: A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
2mo agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: Vamikibart in Participants With Uveitic Macular Edema
3mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Vamikibart in Participants With Uveitic Macular Edema
3mo agoTrial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)
3mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)
3mo agoTrial completedSource (opens the source filing in a new tab)
Phase III trial registered: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
4mo agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
5mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
5mo agoTrial completedSource (opens the source filing in a new tab)
Phase II trial registered: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
7mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
7mo agoTrial completedSource (opens the source filing in a new tab)
Phase III trial registered: Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice
9mo agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
10mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
10mo agoTrial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081
Jul 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081
Jul 2025Trial completedSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
May 2025Trial registeredSource (opens the source filing in a new tab)
Phase I trial registered: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus
Apr 2025Trial completedSource (opens the source filing in a new tab)
Phase II trial registered: A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
Jan 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
Jan 2025Trial completedSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

PHASE1 registered

PHASE1/PHASE2 registered

PHASE1 registered

PHASE3 registered

PHASE2 registered

PHASE3 registered

PHASE2 registered

PHASE1 registered

PHASE3 registered

PHASE3 registered

PHASE3 registered

PHASE3 registered

PHASE2/PHASE3 registered

PHASE1/PHASE2 registered

PHASE3 registered

PHASE4 registered

PHASE3 registered

PHASE2/PHASE3 registered

PHASE1 registered

PHASE3 registered

PHASE3 registered

PHASE1/PHASE2 registered

Study registered

PHASE3 registered

PHASE3 registered

PHASE2 registered

PHASE1/PHASE2 registered

PHASE3 registered

PHASE2 registered

PHASE1 registered

Study registered

PHASE3 registered

PHASE3 registered

Study registered

PHASE3 registered

PHASE1/PHASE2 registered